180 related articles for article (PubMed ID: 21658043)
1. Clarify the negatives of the MIRASOL noninferiority trial.
Strauss RG
Transfusion; 2011 Jun; 51(6):1361-2; author reply 1362-4. PubMed ID: 21658043
[No Abstract] [Full Text] [Related]
2. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
Mirasol Clinical Evaluation Study Group
Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
[TBL] [Abstract][Full Text] [Related]
3. In reply to: "Is the SCID mouse model applicable to human acute lung injury?".
Goodrich RP
Transfusion; 2012 Nov; 52(11):2489-92; author reply 2492-4. PubMed ID: 23140431
[No Abstract] [Full Text] [Related]
4. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
[TBL] [Abstract][Full Text] [Related]
5. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
6. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
7. Treating thrombocytopenia with pathogen-reduced platelets.
Sandler SG
Curr Hematol Rep; 2006 Mar; 5(1):53-4. PubMed ID: 16537046
[No Abstract] [Full Text] [Related]
8. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
9. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model.
Chi X; Zhi L; Vostal JG
Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563
[TBL] [Abstract][Full Text] [Related]
10. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients.
Diedrich B; Ringdén O; Watz E; Shanwell A
Vox Sang; 2009 Oct; 97(3):254-9. PubMed ID: 19508669
[TBL] [Abstract][Full Text] [Related]
13. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
[TBL] [Abstract][Full Text] [Related]
15. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial.
Ypma PF; van der Meer PF; Heddle NM; van Hilten JA; Stijnen T; Middelburg RA; Hervig T; van der Bom JG; Brand A; Kerkhoffs JL;
BMJ Open; 2016 Jan; 6(1):e010156. PubMed ID: 26817642
[TBL] [Abstract][Full Text] [Related]
16. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
17. Platelet transfusion prophylaxis for patients with haematological malignancies: where to now?
Stanworth SJ; Hyde C; Brunskill S; Murphy MF
Br J Haematol; 2005 Dec; 131(5):588-95. PubMed ID: 16351634
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.
AuBuchon JP; Herschel L; Roger J; Taylor H; Whitley P; Li J; Edrich R; Goodrich RP
Transfusion; 2005 Aug; 45(8):1335-41. PubMed ID: 16078923
[TBL] [Abstract][Full Text] [Related]
19. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
20. [No disadvantage of pathogen-reduced platelets?].
Gathof BS
Dtsch Med Wochenschr; 2013 Oct; 138(42):2132. PubMed ID: 24104587
[No Abstract] [Full Text] [Related]
[Next] [New Search]
